Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrin receptors recognizing type I collagen on osteoblasts and mesenchymal stem cells (MSCs) are a specialized group of heterodimeric cell-surface receptors, primarily consisting of the alpha-1 beta-1, alpha-2 beta-1, and alpha-11 beta-1 complexes. These receptors serve as the critical physical and functional link between bone-forming cells and the type I collagen-rich extracellular matrix, which constitutes approximately 90% of the organic bone matrix. In MSCs and osteoblasts, these integrins mediate essential processes including cell attachment, migration, and survival through the activation of signaling cascades such as the FAK/ERK and PI3K/Akt pathways. Specifically, the alpha-2 beta-1 integrin is recognized as a major driver of osteogenic differentiation by upregulating the master transcription factor Runx2. In pathological states like osteoporosis, the expression or activity of these collagen-binding integrins is often diminished, leading to reduced bone formation and increased apoptosis of osteoprogenitor cells. Conversely, in conditions such as cancer metastasis to bone or fibrosis, these receptors may be overexpressed or hyperactivated to facilitate tissue invasion and remodeling. Therapeutic targeting of these integrins involves the use of collagen-mimetic peptides (like GFOGER) to enhance bone regeneration and small molecule inhibitors or monoclonal antibodies to treat inflammatory or metastatic diseases. However, because some members of this group, particularly alpha-2 beta-1, are also vital for platelet adhesion and hemostasis, drug development must address potential safety risks related to bleeding and systemic tissue repair.
Modulation of integrin-mediated cell adhesion and intracellular signaling pathways (e.g., FAK, ERK1/2, and Akt) to regulate osteoblast differentiation, survival, and bone matrix mineralization.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen-binding integrin receptors (CBIs).